関: CCK-8、cholecystokinin octapeptide

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/10 22:53:02」(JST)

wiki en

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical Use

Indications

Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals. It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.^[1]

External links

KINEVAC (sincalide) on NIH.gov

References

^ Kinevac Package Insert

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における合併症のない胆石症 uncomplicated gallstone disease in adults
2. 成人における胆嚢機能障害 functional gallbladder disorder in adults

English Journal

Biliary dyskinesia and symptomatic gallstone disease in children: two sides of the same coin?

Srinath AI1, Youk AO, Bielefeldt K.
Digestive diseases and sciences.Dig Dis Sci.2014 Jun;59(6):1307-15. doi: 10.1007/s10620-014-3126-2. Epub 2014 Apr 9.
BACKGROUND: Despite lack of consensus criteria, biliary dyskinesia (BD) is an increasingly accepted pediatric diagnosis.AIMS: We compared patient characteristics, outcomes, and resource utilization (before and after surgery) between children with BD and symptomatic cholecystolithiasis (LITH).METHODS
PMID 24715545

Gut vagal afferents differentially modulate innate anxiety and learned fear.

Klarer M1, Arnold M1, Günther L2, Winter C2, Langhans W1, Meyer U3.
The Journal of neuroscience : the official journal of the Society for Neuroscience.J Neurosci.2014 May 21;34(21):7067-76. doi: 10.1523/JNEUROSCI.0252-14.2014.
Vagal afferents are an important neuronal component of the gut-brain axis allowing bottom-up information flow from the viscera to the CNS. In addition to its role in ingestive behavior, vagal afferent signaling has been implicated modulating mood and affect, including distinct forms of anxiety and f
PMID 24849343

Intraperitoneal CCK and fourth-intraventricular Apo AIV require both peripheral and NTS CCK1R to reduce food intake in male rats.

Lo CC1, Davidson WS, Hibbard SK, Georgievsky M, Lee A, Tso P, Woods SC.
Endocrinology.Endocrinology.2014 May;155(5):1700-7. doi: 10.1210/en.2013-1846. Epub 2014 Feb 24.
Apolipoprotein AIV (Apo AIV) and cholecystokinin (CCK) are secreted in response to fat consumption, and both cause satiation via CCK 1 receptor (CCK-1R)-containing vagal afferent nerves to the nucleus of the solitary tract (NTS), where Apo AIV is also synthesized. Fasted male Long-Evans rats receive
PMID 24564397

Japanese Journal

Normal values for sincalide cholescintigraphy : comparison of two methods

ZIESSMAN HA
Radiology 221, 404-410, 2001
NAID 30027132700

Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose

JADVAR H
Clin Nucl Med 24, 965-967, 1999
NAID 30018606906

Comparison of intravenous and intramuscular sincalide (C-terminal octapeptide of cholecystokinin) on gallbladder contraction in man

LALYRE Y
Dig Dis Sci 26, 214-247, 1981
NAID 30011637188

Related Pictures

★リンクテーブル★

リンク元	「cholecystokinin octapeptide」「CCK-8」「シンカリド」

「cholecystokinin octapeptide」

Sincalide
Systematic (IUPAC) name
	α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy; category	US: B (No risk in non-human studies);
Legal status	US: ℞-only; Available on a named-patient basis (UK);
Routes of; administration	Intravenous
Identifiers
CAS Registry Number	25126-32-3
ATC code	V04CC03
PubChem	CID: 32800
IUPHAR/BPS	864
ChemSpider	8009168
UNII	M03GIQ7Z6P
KEGG	D05845
ChEMBL	CHEMBL1121
Synonyms	1-De(5-oxo-L-proline)-2-de-L-glutamine-; 5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl); amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-; methylsulfanyl-butanoyl]amino]acetyl]amino]-3-; (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-; butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl); carbamoyl]propanoic acid
Chemical data
Formula	C49H62N10O16S3
Molecular mass	1143.27 g/mol
	SMILES CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N ;
	InChI InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 ; Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N ;
(what is this?) (verify)